Answers are grounded in this paper and cite their sources.
Monoclonal antibody–based PD‐1/PD‐L1 blockade immunotherapy is an innovative approach to cancer treatment. However, its clinical efficacy remains limited, with low response rates in patients, requiring multimodal therapeutic approaches. This study reports the development of synthetic nanohybrid artificial antibodies (SNA) with both PD‐L1 blockade and photothermal effects as multimodal immune checkpoint antagonists for effective combination cancer immunotherapy. Multimodal SNAs are prepared by assembling multivalent tripeptide recognition phases onto rigid scaffolds of WS 2 or MoSe 2 nanosheets with photothermal effect. The SNAs, comprising an FNP tripeptide assembly on nanosheets (MoSe 2 ‐FNP & WS 2 ‐FNP), selectively bind to PD‐L1 with sub‐nanomolar apparent affinity (0.785 nM), thereby effectively blocking its interaction with PD‐1 on T cells. Thorough experimental and computational results reveal that the recognition selectivity of the SNAs for PD‐L1 is attributed to their multivalent hydrogen bonds and hydrophobic interactions with the PD‐L1 epitope. The multimodal MoSe 2 ‐FNP more effectively eradicates tumor cells by combining a PD‐L1 blockade with photothermal effect. The multimodal MoSe 2 ‐FNP‐based combination immunotherapy accelerates the infiltration of antitumoral immune cells into solid tumors in mice, and its therapeutic efficacy is significantly enhanced compared with monoclonal antibody treatment. This SNA‐based cancer immunotherapy thus holds considerable promise as an effective therapeutic avenue for cancer treatment.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: